Clinical and laboratory differences in patients with local and generalized forms of Kaposi sarcoma

The objective: to evaluate clinical and laboratory parameters in local and generalized forms of Kaposi sarcoma (KS) in HIV infected patients to detect predictors of generalized forms of the disease.

Subjects and methods. Case histories of 58 HIV infected patients with KS at the age from 28 to 80 years old were respectively analyzed; they all received treatment in National Medical Research Center of Phthisiopulmonology and Infectious Diseases of the Russian Ministry of Health in 2018-2020. Cases were divided into 2 groups depending on KS manifestations. LF group (local form of KS, n = 28) included the patients with skin lesions; GF group (generalized form of KS, n = 30) included patients with skin lesions and one or several lesions in the other sites: the mucous membrane of gastrointestinal tract, the mucous membrane of tracheobronchial tree, and lung parenchyma.

Results. Patients with the generalized form of KS had a higher frequency of skin lesions on the body (pχ2 = 0.036), face (pχ2 = 0.033), and multiple sites (pχ2 = 0.018). Patients from both groups had low CD4+ count, but it was more severe in GF group (pχ2 = 0.027) with a significant increase of the viral load (pχ2 = 0.047). The predictors of the generalized form of KS are the following: the presence of specific lesions on the skin of body, face and multiple localizations, CD4 level below 125 cells/mcL, increase in the viral load above 5.3log10 copies/ml, reduction of erythrocytes level below 3.1 × 1012 cells/L. Among 24 patients with KS who had 4-6 predictors, 19 (79.2%) had the generalized form. Among KS patients with not a single predictor, there were no cases of generalized form, as well as there were no cases of local forms among patients who had 5 and 6 predictors.

1. Ioannidi E.А., Makarova I.V., Osipov А.V. Clinical characteristics of Kaposi sarcoma in HIV/AIDS patients treated with antiretroviral therapy with consideration of the immune status. Vestn. VolgGMU, 2018, no. 1 (65), pp. 91-93. (In Russ.)

2. Molochkov A.V. Kaposi sarcoma. Lechebnoye Delo, 2006, no. 3, Available: https://cyberleninka.ru/article/n/sarkoma-kaposhi (Accessed: 19.08.2020).

3. On Approval of Instructions for Filling the Annual Form no. 61 of the Federal State Statistical Surveillance on Data on the Contingents of HIV Infected Patients. (Epub.) Edict no. 166 by the Ministry of Health and Social Development of the Russian Federation as of 17.03.2006. (In Russ.) Available: http://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=LAW&n=59648&fld=134&dst=1000000001,0&rnd=0.3950014478740991#09219788075961246

4. UN Summit on Sustainable Development. September 25-27, 2015, UN Headquarters, New-York, the United States of America (Ebub.) (In Russ.) https://www.who.int/mediacentre/events/meetings/2015/un-sustainable-development-summit/ru/

5. Beral V., Peterman T.A., Berkelman R.L. & Jaffe H.W. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet, 335, 1990, pp. 123-128.

6. Cheng F., Pekkonen P., Laurinavicius S., Sugiyama N., Henderson S., Günther T., Rantanen V., Kaivanto E., Aavikko M., Sarek G., Hautaniemi S., Biberfeld P., Aaltonen L., Grundhoff A., Boshoff C., Alitalo K., Lehti K., Ojala PM. KSHV-initiated noych activation leads to membrane-type-1 matrix metalloproteinase-dependent lymphatic endothelial-to-mesenchymal transition. Cell.Host.Microbe, 2011, vol. 10, no. 6, pp. e577-е590.

7. Dalpa E., Gourvas V., Baritaki S., Miyakis S., Samaras V., Barbatis C., Sourvinos G., Spandidos D. A. High prevalence of Human Herpes Virus 8 (HHV-8) in patients with Warthin's tumors of the salivary gland. J.Clin.Virology, 2008, vol. 42, iss. 2, pp. 182-185. ISSN 1386-6532, https://doi.org/10.1016/j.jcv.2008.01.015.

8. Guasparri I., Keller S.A., Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J.Exp.Med., 2004, no. 199, pp. 993-1003.

9. Kaaya E.E., Parravicini C., Sundelin B., Mgaya E., Kitinya J., Lema L., Luande J., Biberfeld P. Spindle cell ploidy and proliferation in endemic and epidemic African Kaposi’s sarcoma. Eur.J.Cancer, 1992, no 28A, pp. 1890-1894. (doi:10.1016/0959-8049(92) 90030-6).

10. Koyuncu I., Gönel A., Ozcan E., Temiz E., Toprak S., Akkafa F., Binici I. Single nucleotide polymorphism analysis in HIV and Kaposi's Sarcoma disease by microarray technique. Curr.HIV.Res., 2020, vol. 18, no. 3, pp. 154-164. doi: 10.2174/1570162X18666200130100654.

11. Krown S.E., Testa M.A., Huang J. AIDS-related Kaposi’s sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification.. J.Clin.Oncol., 1997, no. 15, pp. 3085-3092.

12. Monini P., de Lellis L., Fabris M., Rigolin F., Cassai E. Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen. N. Engl.J.Med., 1996, no. 334, pp. 1168-1172.

13. Mosam A., Shaik F., Uldrick T. S., Esterhuizen T., Friedland G. H., Scadden D.T. et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J.Acquir.Immune. Defic.Syndr., 2012, no. 60, pp. 150-157.

14. Pauk J., Huang M.L., Brodie S.J., Wald A., Koelle D.M., Schacker T. et al. Mucosal shedding of human herpesvirus 8 in men. N. Engl.J.Med., 2000, no. 343, pp. 1369-1377.

15. Paul A.G., Chandran B., Sharma-Walia N. Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi’s sarcoma-associated herpes virus associated malignancies. Transl.Res., 2013, no. 162, pp. 77-92.

16. Poizot-Martin I., Obry-Roguet V., Duvivier C., Lions C., Huleux T., Jacomet C., Ferry T., Cheret A., Allavena C., Bani-Sadr F., Palich R., Cabié A., Fresard A., Pugliese P., Delobel P., Lamaury I., Hustache-Mathieu L., Brégigeon S., Makinson A., Rey D. Dat'AIDS study group. Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015. J.Eur. Acad.Dermatol.Venereol., 2020, Jan 17. doi: 10.1111/jdv.16204. (Epub ahead of print).

17. Rivas C., Thlick A.E., Parravicini C., Moore P.S., Chang Y. Kaposi’s sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J.Virol., 2001, no. 75, pp. 429-438.

18. Rohner E., Wyss N., Heg Z., Faralli Z., Mbulaiteye S.M., Novak U., Zwahlen M., Egger M., Bohlius J. HIV and human herpesvirus 8 co-infection across the globe: Systematic review and meta-analysis. Int.J.Cancer, 2016, vol. 138, no. 1, pp. 45-54.

19. Rohner E., Wyss N., Trelle S., Mbulaiteye S. M., Egger M., Novak U., Zwahlen M., Bohlius J. HHV-8 seroprevalence: a global view. Syst.Rev., 2014, Feb. 12, no. 3, pp. 11.

20. Sadagopan S., Sharma-Walia N., Veettil M.V., Bottero V., Levine R., Vart R.J., Chandran B. Kaposi’s sarcoma-associated herpesvirus upregulates angiogenin during infection of human dermal microvascular endothelial cells, which induces 45S rRNA synthesis, antiapoptosis, cell proliferation, migration, and angiogenesis. J.Virol., 2009, no. 83, pp. 3342-3364.

21. Sarek G., Jarviluoma A., Ojala P.M. KSHVviral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas. Blood, 2006, no. 107, pp. 725-732.

22. Schubert U., Antón L.C., Bacík I., Cox J.H., Bour S., Bennink J.R., Orlowski M., Strebel K., Yewdell J.W. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J.Virol., 1998, vol. 72, no. 3, pp. 2280-2288.